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Implication for health policy/practice/research/medical education:
After a long time, the efficacy of vaccination against hepatitis B could be decreased and thus 
for maintenance of protective antibody titer, booster dose of vaccine is required. It seems that 
additional studies with different dose of vaccine, duration and method are necessary for finding 
of the best method of vaccination in terms of safety, effectiveness and convenience application of vaccine among hemodialysis patients.  
A R T I C L E  I N F O
Keywords:Vaccination
Hepatitis B Hemodialysis
Article History:Received: 1 March 2013Accepted: 28 March 2013
ePublished: 10 October 2013
Article Type:Hypothesis
Please cite this paper as: Momeni A. The best method of hepatitis B vaccination in hemodialysis patients? J Renal Inj Prev 2013; 2(4): 125-126. DOI: 10.12861/jrip.2013.40
*Corresponding author: Ali Momeni, Department of Nephrology, Shahrekord University of Medical Sciences, Shahrekord, Iran.   E-mail:  alimomeny@ yahoo.com
Hepatitis B is the most important cause of cirrhosis in many countries. Hemodialysis patients are susceptible 
to hepatitis due to repeated contact with dialysis machines 
and blood products (1). For immunization against hepatitis 
B, intramuscular (deltoid) vaccination in months 0, 1 and 
6 is the standard method in normal population; and after 
immunization, HBS antibody titer should be greater than 10 mIU/mL (2). Approximately 90-95% of healthy people and 45-50% of dialysis patients properly respond to vaccination (3). In dialysis patients, although, usual method of 
vaccination is double dose of recombinant vaccine in months 
0, 1, 2 and 6; due to insufficient response and rapid decline 
on antibody titer, different methods of vaccination were 
used in hemodialysis patients. In a cross-sectional study in hemodialysis patients of Hajar Hospital of Shahrekord, 
Iran, 24 cases of 78 hemodialysis patients without any appropriate response to conventional method of vaccination 
(double dose in 0, 1 and 6 months) and antibody titer less 
than 10 mIU/mL, were randomly assigned to intramuscular 
and intradermal groups. In intradermal (ID) group, 10 µg 
(0.5 ml) recombinant vaccine was prescribed every 2 weeks 
to 6 months, but in intramuscular (IM) group, 40 µg (2 ml) 
at 0, 1, 2 and 6 months were prescribed. At the beginning 
of the study, mean HBsAg specific antibody titer in patients 
was 4.4±3.1 mu/ml and after 1 month and 3 months, mean 
HBsAg antibody titer was 190.4 ± 59 mIU/mL and 223.3 ± 
83.9 mIU/mL, respectively (p< 0.001). In both groups, the 
antibody titers were checked after 1, 3, 14 and 18 months 
after the last vaccination. Eight patients excluded from 
study because of transplantation, death or uncooperation. 
Furthermore, after 14 and 18 months, HBS antibody titer was 
rechecked in 16 remaining patients.  Mean antibody titer in 14th and 20th month was 144±64 mIU/mL and 45±34ug/ml, 
respectively. There was no significant difference between 
antibody titer in two groups in all stages of the study. We 
found that the antibody titer decreased significantly over 
time, although at the end of the study, antibody titer was 
slightly more than minimum of protective titer (greater than 
10 Iu/ml). However, other studies reported different and 
occasionally controversial results. For example, in Morais’ 
study, patients with antibody titer less than 10 mu/ml were 
received low dose of intradermal HB vaccine; and later in 
82% of patients, antibody titer were greater than 10 mIU/mL after 12 monthes of vaccination (4). In Sorkhi’s study, 
after 6 months of vaccination, low dose intradermal and 
subcutaneous vaccination resulted in less seroconversion 
versus intramuscular method (5). Similar to our results, 
Somboonsilp showed that in end-stage renal disease ( 
ESRD) patients,  there were no significant difference in 
seroconversion rates (anti HBs levels above 10 mIU/mL) 
between the intradermal and intramuscular groups at months 1, 2 and 7 (6). As a result, in majority of studies, after 
a long time, the efficacy of vaccination could be decreased 
and thus for maintenance of protective antibody titer, 
booster dose of vaccine is required. It seems that additional 
studies with different dose of vaccine, duration and method 
are necessary for finding of the best method of vaccination in terms of safety, effectiveness and convenience application 
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of vaccine among hemodialysis patients.
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